The Distrio turns a proven track record in the global movement of regulated cannabinoid products into a competitive edge for our clients. We help you accelerate time-to-revenue and capture market share faster. We blend enterprise-level pharmaceutical expertise in product development, quality assurance, and regulatory affairs with hands-on experience in Licensed Producer (LP) operations from seed-to-sale.. With a global network of licensed cannabinoid producers capable of shipping to any legal jurisdiction, the Distrio provides safe and trustworthy assistance across the cannabinoid supply chain. We want you to trust your supply.
distrioGPT is our custom LLM developed for clients dealing with high-leverage quality events and technical content. It streamlines quality assurance and content creation workflows by equipping clients with self-service tools and custom AI agents—whether as quality assistants, brand ambassadors, or content creators. Beyond AI, we deliver advanced web development and marketing automation to launch digital strategies quickly and at scale, while supporting content creation across all media formats.
The Distrio Network
The Distrio Network is a content hub for procurement, quality assurance, and technical professionals in the global cannabinoid supply chain. With cannabinoid-specific sites, professionals across the global supply chain will find in-depth and engaging content about these molecules and their markets.
CBD: The Therapeutic Non-Psychoactive Cannabinoid
Cannabidiol (CBD) is a non-psychoactive cannabinoid that has gained popularity for its potential therapeutic benefits. Unlike THC, CBD does not produce a high, making it appealing for medical use. It interacts with various receptors in the body, notably enhancing the activity of serotonin 1A receptors, which contributes to its anxiolytic (anxiety-reducing) effects. CBD’s low oral bioavailability (~6%) is due to its extensive first-pass metabolis. Clinically, CBD has been shown to reduce seizure frequency in epilepsy, particularly in conditions like Dravet syndrome. Ongoing research continues to explore its efficacy in treating anxiety disorders, chronic pain, and inflammation.
CBG: The Emerging Cannabinoid
Cannabigerol (CBG) is a lesser-known, non-psychoactive cannabinoid that is gaining attention for its potential health benefits. CBG is unique because it acts as a precursor to other cannabinoids, including THC and CBD. This means that during the cannabis plant’s growth, CBG is converted into these more prevalent cannabinoids. CBG is being studied for its anti-inflammatory and neuroprotective properties, with early research suggesting it may be beneficial for conditions like inflammatory bowel disease and glaucoma. Although clinical trials are limited, the ongoing research into CBG’s pharmacological effects is promising, highlighting its potential as a therapeutic agent without psychoactive effects.
THC: The Psychoactive Cannabinoid
Tetrahydrocannabinol (THC) is the most well-known cannabinoid, primarily responsible for the psychoactive effects of cannabis. When consumed, THC is rapidly absorbed into the bloodstream, especially when inhaled, with a bioavailability ranging from 10-35%. This means that a significant portion of THC enters the bloodstream and reaches the brain, where it binds to CB1 receptors, producing the characteristic “high.” A unique aspect of THC is its conversion into 11-hydroxy-THC, a metabolite that enhances its psychoactive effects, through the liver. Beyond its recreational use, THC is being studied in clinical trials for its potential to alleviate chronic pain and spasticity associated with multiple sclerosis. These trials aim to harness THC’s analgesic properties while managing its psychoactive effects.
Contact Us
Sean Karl, Managing Director
The Distrio
+1-778-839-5855